Logo image of PDSB

PDS BIOTECHNOLOGY CORP (PDSB) Stock Fundamental Analysis

USA - NASDAQ:PDSB - US70465T1079 - Common Stock

1.165 USD
+0.01 (+0.43%)
Last: 9/15/2025, 9:35:58 AM
Fundamental Rating

1

Taking everything into account, PDSB scores 1 out of 10 in our fundamental rating. PDSB was compared to 540 industry peers in the Biotechnology industry. PDSB has a bad profitability rating. Also its financial health evaluation is rather negative. PDSB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PDSB has reported negative net income.
PDSB had a negative operating cash flow in the past year.
PDSB had negative earnings in each of the past 5 years.
In the past 5 years PDSB always reported negative operating cash flow.
PDSB Yearly Net Income VS EBIT VS OCF VS FCFPDSB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

PDSB has a worse Return On Assets (-90.43%) than 72.59% of its industry peers.
PDSB's Return On Equity of -229.34% is on the low side compared to the rest of the industry. PDSB is outperformed by 69.26% of its industry peers.
Industry RankSector Rank
ROA -90.43%
ROE -229.34%
ROIC N/A
ROA(3y)-69.42%
ROA(5y)-56.3%
ROE(3y)-151.69%
ROE(5y)-107.33%
ROIC(3y)N/A
ROIC(5y)N/A
PDSB Yearly ROA, ROE, ROICPDSB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PDSB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PDSB Yearly Profit, Operating, Gross MarginsPDSB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

PDSB has more shares outstanding than it did 1 year ago.
PDSB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PDSB has a worse debt to assets ratio.
PDSB Yearly Shares OutstandingPDSB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PDSB Yearly Total Debt VS Total AssetsPDSB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.73, we must say that PDSB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.73, PDSB is doing worse than 68.15% of the companies in the same industry.
A Debt/Equity ratio of 0.81 indicates that PDSB is somewhat dependend on debt financing.
PDSB has a worse Debt to Equity ratio (0.81) than 74.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Altman-Z -7.73
ROIC/WACCN/A
WACCN/A
PDSB Yearly LT Debt VS Equity VS FCFPDSB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PDSB has a Current Ratio of 2.92. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.92, PDSB is not doing good in the industry: 64.44% of the companies in the same industry are doing better.
A Quick Ratio of 2.92 indicates that PDSB has no problem at all paying its short term obligations.
PDSB has a worse Quick ratio (2.92) than 62.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
PDSB Yearly Current Assets VS Current LiabilitesPDSB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.20% over the past year.
EPS 1Y (TTM)25.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PDSB will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.59% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.13%
EPS Next 2Y13.15%
EPS Next 3Y7.17%
EPS Next 5Y19.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PDSB Yearly Revenue VS EstimatesPDSB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
PDSB Yearly EPS VS EstimatesPDSB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PDSB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PDSB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PDSB Price Earnings VS Forward Price EarningsPDSB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PDSB Per share dataPDSB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.15%
EPS Next 3Y7.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PDSB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (9/15/2025, 9:35:58 AM)

1.165

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners18.09%
Inst Owner Change-10.2%
Ins Owners2.11%
Ins Owner Change0%
Market Cap54.32M
Analysts82.22
Price Target7.65 (556.65%)
Short Float %4.24%
Short Ratio3.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.15%
Min EPS beat(2)11.76%
Max EPS beat(2)16.54%
EPS beat(4)3
Avg EPS beat(4)12.93%
Min EPS beat(4)-2.15%
Max EPS beat(4)25.59%
EPS beat(8)7
Avg EPS beat(8)18.7%
EPS beat(12)8
Avg EPS beat(12)1.93%
EPS beat(16)10
Avg EPS beat(16)0.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.48%
EPS NQ rev (3m)-4.06%
EPS NY rev (1m)8.24%
EPS NY rev (3m)10.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.4
P/tB 3.4
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.43%
ROE -229.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.42%
ROA(5y)-56.3%
ROE(3y)-151.69%
ROE(5y)-107.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -7.73
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
EPS Next Y19.13%
EPS Next 2Y13.15%
EPS Next 3Y7.17%
EPS Next 5Y19.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.96%
EBIT Next 3Y-17.51%
EBIT Next 5Y-13.4%
FCF growth 1Y-9.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.38%
OCF growth 3YN/A
OCF growth 5YN/A